四川千里倍益康医疗科技股份有限公司 2024 年度 非经营性资金占用及其他关联资金往来的 专项说明 | 索引 | 页码 | | --- | --- | | 专项说明 | 1-2 | | 非经营性资金占用及其他关联资金往来情况汇总表 | 1-1 | 关于四川千里倍益康医疗科技股份有限公司 2024 年度非经营性资金占用及其他关联资金往来的专项说明 XYZH/2025CDAA1B0200 四川千里倍益康医疗科技股份有限公司 四川千里倍益康医疗科技股份有限公司全体股东： 我们按照中国注册会计师审计准则审计了四川千里倍益康医疗科技股份有限公司 （以下简称倍益康公司）2024 年度财务报表，包括 2024 年 12 月 31 日的合并及母公司 资产负债表、2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公 司 股 东 权 益 变 动 表 以 及 财 务 报 表 附 注 ， 并 于 2025 年 4 月 17 日 出 具 了 XYZH/2025CDAA1B0198 号无保留意见的审计报告。 根据中国证券监督管理委员会《上市公司监管指引第 8 号——上市公司资金往来、 对外担保的监管要求》（证监会公告[ ...

四川千里倍益康医疗科技股份有限公司 2024 年度 审计报告 | 索引 | | 页码 | | --- | --- | --- | | 审计报告 | | 1-4 | | 公司财务报表 | | | | — | 合并资产负债表 | 1-2 | | — | 母公司资产负债表 | 3-4 | | — | 合并利润表 | 5 | | — | 母公司利润表 | 6 | | — | 合并现金流量表 | 7 | | — | 母公司现金流量表 | 8 | | — | 合并股东权益变动表 | 9-10 | | — | 母公司股东权益变动表 | 11-12 | | — | 财务报表附注 | 13-81 | | 信永 中和合分析 工 京 本 城 北 京 市 东城 朝 北 大 街 我 电话: +86 (010) 6554 2288 | | | | --- | --- | --- | | telephone: +86 (010) 6554 2288 | 8 号富华大厦 A 座 9 层 | | | ShineWing | 9/F, Block A, Fu Hua Mansion, | | | No.8, Chaoyangmen Beidaj ...

四川千里倍益康医疗科技股份有限公司 2024 年度 募集资金年度存放与使用情况鉴证报告 | 鉴证报告 | | 1-2 | | --- | --- | --- | | 索引 关于募集资金 2024 | 年度存放与使用情况的专项报告 | 页码 1-11 | 募集资金年度存放与使用情况鉴证报告 XYZH/2025CDAA1B0201 四川千里倍益康医疗科技股份有限公司 我们按照《中国注册会计师其他鉴证业务准则第 3101 号-历史财务信息审计或审阅 以外的鉴证业务》的规定执行了鉴证工作，以对募集资金年度存放与使用情况专项报告 是否不存在重大错报获取合理保证。在执行鉴证工作的过程中，我们实施了询问、检查、 重新计算等我们认为必要的鉴证程序，选择的程序取决于我们的职业判断。我们相信， 我们的鉴证工作为发表意见提供了合理的基础。 我们认为，倍益康公司上述募集资金年度存放与使用情况专项报告已经按照北京证 券交易所相关规定编制，在所有重大方面如实反映了倍益康公司 2024 年度募集资金的 实际存放与使用情况。 1 鉴证报告（续） XYZH/2025CDAA1B0201 四川千里倍益康医疗科技股份有限公司 四川千里倍益康医疗科 ...

证券代码：870199 证券简称：倍益康 公告编号：2025-020 四川千里倍益康医疗科技股份有限公司 2024 年度独立董事述职报告（易阳） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 本人作为四川千里倍益康医疗科技股份有限公司（以下简称"公司"）的独 立董事，严格按照《证券法》《公司法》《北京证券交易所上市公司持续监管指引 第 1 号——独立董事》以及《公司章程》《独立董事工作制度》等法律法规和公 司有关规定，切实履行独立董事职责，认真、勤勉地行使公司所赋予独立董事的 权利，充分发挥独立董事作用，维护公司整体利益和全体股东的利益，积极出席 相关会议，对各项议案进行认真审议，完成了董事会交办的各项作任务。现将 2024 年度履行独立董事职责的工作情况汇报如下： 一、出席会议的情况 会会议 1 次、独立董事专门会议 1 次，未发生需董事会战略与发展委员会、董事 会提名委员会审议事项。本人作为董事会审计委员会主任委员积极出席董事会审 计委员会会议以及独立董事专门会议，切实履行审计委员与独立董事职责， ...

证券代码：870199 证券简称：倍益康 公告编号：2025-022 四川千里倍益康医疗科技股份有限公司 2024 年度独立董事述职报告（王伦刚） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 本人作为四川千里倍益康医疗科技股份有限公司（以下简称"公司"）的独 立董事，严格按照《证券法》《公司法》《北京证券交易所上市公司持续监管指引 第 1 号——独立董事》以及《公司章程》《独立董事工作制度》等法律法规和公 司有关规定，切实履行独立董事职责，认真、勤勉地行使公司所赋予独立董事的 权利，充分发挥独立董事作用，维护公司整体利益和全体股东的利益，积极出席 相关会议，对各项议案进行认真审议，完成了董事会交办的各项作任务。现将 2023 年度履行独立董事职责的工作情况汇报如下： 一、出席会议的情况 （一）出席董事会、股东大会的情况 2024 年度公司共召开董事会会议 7 次，股东大会 3 次。本人积极参加了公 司召开的董事会及股东大会，认真审阅相关资料，参与各项议题的讨论并提出合 理建议，以严谨的态度行使表决权 ...

证券代码：870199 证券简称：倍益康 公告编号：2025-021 四川千里倍益康医疗科技股份有限公司 2024 年度独立董事述职报告（聂采现） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 本人作为四川千里倍益康医疗科技股份有限公司（以下简称"公司"）的独 立董事，严格按照《证券法》《公司法》《北京证券交易所上市公司持续监管指引 第 1 号——独立董事》以及《公司章程》《独立董事工作制度》等法律法规和公 司有关规定，切实履行独立董事职责，认真、勤勉地行使公司所赋予独立董事的 权利，充分发挥独立董事作用，维护公司整体利益和全体股东的利益，积极出席 相关会议，对各项议案进行认真审议，完成了董事会交办的各项作任务。现将 2024 年度履行独立董事职责的工作情况汇报如下： 一、出席会议的情况 （一）出席董事会、股东大会的情况 2024 年度公司共召开董事会会议 7 次，股东大会 3 次。本人积极参加了公 司召开的董事会及股东大会，认真审阅相关资料，参与各项议题的讨论并提出合 理建议，以严谨的态度行使表决权 ...

证券代码：870199 证券简称：倍益康 公告编号：2025-035 四川千里倍益康医疗科技股份有限公司 舆情管理制度 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 四川千里倍益康医疗科技股份有限公司于 2025 年 4 月 17 日召开了第三届董 事会第二十三次会议，会议审议通过了《关于制定公司<舆情管理制度>的议案》， 表决结果：同意 8 票；反对 0 票；弃权 0 票。本议案无需提交股东大会审议。 二、 制度的主要内容，分章节列示： 四川千里倍益康医疗科技股份有限公司舆情管理制度 第一章 总则 第一条 为提高四川千里倍益康医疗科技股份有限公司（以下简称"公司"） 应对各类舆情的能力，建立健全舆情监测、评估、预警及快速反应和应急处置机 制，及时、妥善处理各类舆情对公司股价、商业信誉及正常生产经营活动造成的 影响，切实保护投资者和公司的合法权益，根据《中华人民共和国公司法》、《中 华人民共和国证券法》、《上市公司信息披露管理办法》等相关法律法规、规范性 文件以及《四川千里倍益康 ...

Innovation and Product Development - The company added 141 new patents during the reporting period[4] - The portable deep muscle massager was recognized as one of the first "Chengdu Industrial Fine Products" by local authorities on March 1, 2024[4] - A new subsidiary, Foshan Beika Electronic Commerce Co., Ltd., was established to expand online sales channels on March 14, 2024[4] - A wholly-owned subsidiary, Tibet Yanluo Technology Co., Ltd., was set up on May 29, 2024, to promote oxygen therapy products in high-altitude regions[4] - The company received medical device registration certificates for several products, including the biological stimulation feedback instrument and the medium-frequency therapy instrument, on September 18 and December 31, 2024, respectively[4] - The portable pneumatic massage system obtained FDA 510(k) registration on October 8, 2024[4] - The company is developing a series of new medical devices, including a pelvic floor rehabilitation device and a portable pressure massage system, with several products already receiving medical device registration[86] - The company has achieved significant advancements in its product lines, including the introduction of smart control technology in its high-frequency electrotherapy products[86] - The company has expanded its product line with the launch of a new portable oxygen machine, which meets high-altitude supply needs and is currently in mass production[87] - The company has developed a new series of medical oxygen machines designed to alleviate oxygen deficiency, ensuring stable oxygen concentration above 90%[87] - The company has introduced a new line of portable oxygen machines that can switch between pulse and continuous modes, catering to outdoor and high-altitude travel needs[87] - The company has enhanced its rehabilitation product offerings with the introduction of portable biofeedback devices, meeting the needs for pelvic floor and neurological rehabilitation[88] - The company has developed a new series of ultrasound and electrical stimulation therapy devices, which are designed for pain rehabilitation[88] - The company has optimized its magnetic therapy products to meet clinical demands for various diseases, achieving industry-leading technical indicators[88] - The company has developed 8 different models of massage guns, enhancing market competitiveness and brand recognition through continuous product iteration[175] - The new massage gun features a variable amplitude adjustment system, allowing for a massage depth of 4-10mm, catering to diverse user needs[175] - The mid-frequency electrotherapy device allows for independent output across 4 channels, enabling simultaneous treatment of multiple areas[175] - The company’s products are positioned above average in several key performance indicators compared to similar products in the market[176] - The company is focused on enhancing user experience through innovative designs and advanced technology in its product offerings[175] Financial Performance - The company's operating revenue for 2024 was CNY 291.23 million, a decrease of 12.78% compared to CNY 333.89 million in 2023[24] - The net profit attributable to shareholders for 2024 was CNY 27.78 million, down 36.70% from CNY 43.89 million in 2023[24] - The gross profit margin improved to 37.99% in 2024 from 36.73% in 2023[24] - Total assets increased by 4.71% to CNY 690.47 million in 2024, compared to CNY 659.43 million in 2023[26] - Total liabilities rose by 17.19% to CNY 168.37 million in 2024, up from CNY 143.67 million in 2023[26] - The company's cash flow from operating activities decreased by 47.00% to CNY 29.99 million in 2024, compared to CNY 56.58 million in 2023[26] - The weighted average return on equity based on net profit attributable to shareholders was 5.33% in 2024, down from 8.49% in 2023[24] - The company reported a net profit margin decline, with a net profit growth rate of -36.70% in 2024 compared to -37.33% in 2023[26] - The company achieved operating revenue of CNY 291,228,708.87 and a net profit attributable to shareholders of CNY 27,781,140.47 during the reporting period[41] - Total assets as of December 31, 2024, amounted to CNY 690,471,403.90, with a net cash flow from operating activities of CNY 29,985,257.05[41] - Cash and cash equivalents increased by CNY 35,542,800, representing a growth of 56.96% compared to the previous period[47] - Construction in progress rose by CNY 124,147,400, reflecting a 99.40% increase due to ongoing investments in the Chengdu smart manufacturing base[47] - Long-term borrowings increased by CNY 24,992,000, a rise of 249.92%, primarily due to mortgage loans for property purchases[47] - The company experienced a 151.99% increase in financial expenses, primarily due to reduced bank deposit interest income[53] - The impairment loss on assets was recorded at CNY 396.46 thousand, reflecting a new provision for inventory depreciation[53] - The company reported a significant increase in contract liabilities, which rose by 60.65% to CNY 2.73 million, indicating a rise in customer prepayments[51] - Domestic revenue fell by 38.27% to CNY 142.99 million, while overseas revenue increased by 45.00% to CNY 148.23 million[62] - Revenue from muscle massagers, the company's main product, reached CNY 227.32 million, representing 78.85% of total operating income, highlighting the company's dependency on a single product[103] Market and Industry Trends - The global rehabilitation medical device market is expected to reach USD 50 billion by 2025, with a compound annual growth rate of approximately 7%[43] - The Chinese rehabilitation medical device market is projected to reach CNY 123.15 billion by 2030, indicating significant growth potential[43] - The health consumption trend is evolving, with consumers increasingly seeking preventive care and wellness solutions rather than just medical treatment[161] - The global wellness industry is projected to reach $5 trillion in 2021 and is expected to grow to approximately $7 trillion by 2025, with a compound annual growth rate (CAGR) of 9.90%[161] - China's health industry is targeted to exceed 8 trillion yuan by 2020 and reach over 16 trillion yuan by 2030, with an estimated CAGR of 7.18%[163] - The demand for rehabilitation medical devices is expected to create a market need of approximately 120 billion yuan from 2021 to 2030, based on a projected shortfall of 400,000 rehabilitation beds[167] - The number of rehabilitation medicine beds in China was reported at 306,846 by the end of 2020, indicating significant growth potential in the sector[167] - The integration of new technologies such as big data, artificial intelligence, and wearable devices is driving innovation in the health industry, leading to the development of new products and services[161] - The rehabilitation medical device market is categorized into assessment devices, training devices, and therapy devices, each playing a crucial role in patient recovery[164] - The Chinese government is actively promoting the development of the health industry as a pillar of the national economy, emphasizing the importance of innovation and technology[163] - The rehabilitation medical device market is expected to see increased investment, with an estimated 300,000 yuan per bed for rehabilitation equipment in hospitals[167] - The home medical device market is experiencing a steady increase in penetration rate, supported by aging population trends and rising health awareness[168] - The home rehabilitation medical device segment is anticipated to become a new driving force for the development of home medical devices due to increased consumer demand for self-care and remote diagnosis services[170] - The consumer-grade smart hardware market in China is projected to reach approximately 1.3 trillion RMB by 2025, driven by the growth of IoT products and advancements in digital infrastructure[174] Corporate Governance and Compliance - The company has implemented various audit procedures to ensure the accuracy and reliability of its revenue recognition policies[90] - The company has confirmed that there are no relationships affecting the independence of its auditing firm, ensuring objective and accurate financial reporting[91] - The company has maintained compliance with corporate governance regulations, ensuring investor rights and information transparency[189] - The company has established a complete modern corporate governance system, ensuring shareholder rights and participation in decision-making processes[190] - The company strictly followed legal procedures for major operational decisions and investments, with no violations reported during the period[191] - The company ensured that all meeting procedures complied with legal and regulatory requirements, including notice and voting processes[196] - The company has committed to transparency in its fundraising and usage reports, ensuring compliance with regulations[195] - The company has established an Investor Relations Management System to enhance communication with investors and improve transparency, ensuring timely disclosure of relevant information[198] - The Audit Committee reviewed the internal audit department's work plan and provided guidance, ensuring effective execution of internal control systems[200] - The company has committed to maximizing shareholder value through improved corporate governance and investor relations practices[198] Research and Development - R&D expenditure for the current period is CNY 17,103,465.59, accounting for 5.87% of operating revenue, compared to CNY 20,400,005.98 and 6.11% in the previous period[82] - The proportion of R&D personnel in the total workforce is stable at approximately 15.81%, with a total of 79 R&D staff[83] - The company’s R&D investment capitalized rate remains at 0%, indicating a focus on immediate expense recognition rather than capitalization[83] - The company has implemented a comprehensive R&D management system in compliance with ISO13485 standards, ensuring quality control throughout the product development process[181] - The company has established a risk management plan for product development, identifying and controlling safety-related risks[181] - The top five R&D projects incurred a total expenditure of 9,875,509.29 yuan during the reporting period, with the variable amplitude deep muscle massager being the highest at 3,671,000.50 yuan[184] - The company has obtained multiple domestic and international patent authorizations for its products, including the portable pressure massage system which has passed FDA510(K) approval[180] Employee and Shareholder Relations - The company has a total of 502 employees at the end of the reporting period, down from 544 at the beginning, reflecting a net decrease of 42 employees[150] - The board of directors consists of 8 members, while the supervisory board has 3 members, and there are 5 senior management personnel[150] - The total number of employees in the R&D department decreased from 86 to 79, with 16 new hires and 23 departures during the reporting period[150] - The company has implemented a comprehensive employee training program focusing on job skills, professional knowledge, and safety[151] - The company has no retired employees for which it needs to bear costs during the reporting period[151] - The total number of shares held by the board members and senior management is 41,211,072, accounting for 60.44% of the total shares[147] - The company’s financial compensation for directors and senior management is based on their positions and individual performance[149] - The company has adopted an employee stock ownership plan for core technical personnel to align their interests with the company's development[105] - The company has established a reasonable profit distribution plan to share operational results with shareholders while ensuring sustainable development[95] Strategic Focus and Future Plans - The company plans to continue focusing on the rehabilitation technology sector, enhancing its product offerings in health and wellness[38] - The company plans to implement a dual-driven strategy of "ODM + own brand" to enhance brand exposure and customer reach[41] - The company aims to leverage new technologies such as big data and AI to drive innovation in health products and services[44] - The company plans to increase investment in "medical + consumer" resources to enhance its position as a global leader in comprehensive rehabilitation technology[98] - The company aims to expand its overseas market presence and sales channels to strengthen its core product advantages in the industry[99] - The company plans to achieve a production capacity of 203,000 units per year for various therapeutic products by December 31, 2025, with a total investment of 403.184 million yuan[179] - The company is focusing on building an integrated online and offline marketing network to enhance customer data management and marketing strategies[42] - The company has not encountered any significant uncertainties affecting its future business strategy during the reporting period[100]

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.4079 | 0.6444 | -36.7 | 1.8288 | | 每股净资产（元） | 0 | 7.54 | -100 | 10.65 | | 每股公积金(元) | 4.92 | 4.91 | 0.2 | 6.85 | | 每股未分配利润(元) | 1.37 | 1.31 | 4.58 | 2.42 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 2.91 | 3.34 | -12.87 | 3.91 | | 净利润(亿元) | 0.28 | 0.44 | -36.36 | 0.7 | | 净资产收益率(%) | 5.33 | 8.49 | -37.22 | 37.41 | 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 2060.47万股，累计占流通股比： 55.39%，较上期变化： -87.00万 股。 | 名称 持有 ...

4月8日至11日，第91届中国国际医疗器械（春季）博览会CMEF在上海国家会展中心成功举办。倍益康 携众多康复类新产品亮相，涉及电疗、力疗、氧疗、肌电生物反馈、理疗机器人等领域，产品有干扰电 治疗仪、理疗机器人、生物刺激反馈仪、盆底康复治疗仪、便携制氧机、5升医用制氧机、可变振幅筋 膜枪、家用中频治疗仪、短波治疗仪等。 电疗 — 疼痛康复 展望未来，倍益康将继续秉承"康复科技 关护生命"的企业使命，聚焦深耕康复行业，依托理疗机器 人、干扰电治疗仪、盆底康复治疗仪等创新产品，不断拓展市场份额，不断夯实电疗、力疗、氧疗、肌 电生物反馈、理疗机器人等领域的竞争力，提升品牌影响力，为客户提供高品质的康复产品和服务。 理疗机器人成为倍益康展位的焦点，在四天的展会期间体验者络绎不绝。倍益康通过融合物理治疗与六 轴协作机器人技术，推出了智能艾灸机器人、射频理疗机器人、按摩理疗机器人等系列产品，可满足多 场景的理疗康复需求，大幅度降低对人工的依赖，提升物理按摩和治疗的效率。 氧疗系列 倍益康此次参展的氧疗系列产品非常丰富，满足了各种场景的供氧需求:在户外使用的便携制氧机、水 杯式保健制氧机；在室内使用的5升静音款医用制氧机； ...